All Stories

  1. Advances in Radioligand Theranostics in Oncology
  2. Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives
  3. Prognostic Value of PSMA PET/CT in Prostate Cancer
  4. Prostate Cancer Skeletal Metastasis: A Spontaneous Evolution from Osteolytic to Osteoblastic Morphology without Treatment
  5. Integrated Genomic Analysis of Primary Prostate Tumor Foci and Corresponding Lymph Node Metastases Identifies Mutations and Pathways Associated with Metastasis
  6. PET/CT and SPECT/CT for Infection in Joints and Bones: An Overview and Future Directions
  7. Correlation between [68Ga]Ga-FAPI-46 PET Imaging and HIF-1α Immunohistochemical Analysis in Cervical Cancer: Proof-of-Concept
  8. Aberrant Vascular Anatomy Associated With Artifactual Focal Avidity in the Liver on PSMA PET
  9. Differences in Tumour Aggressiveness Based on Molecular Subtype and Race Measured by [18F]FDG PET Metabolic Metrics in Patients with Invasive Carcinoma of the Breast
  10. 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings
  11. Impact of 18F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy
  12. The SARS-COV-2 Seroprevalence among Oncology Patients
  13. Molecular Imaging of Tuberculosis
  14. [68Ga]Ga-NODAGAZOL uptake in atherosclerotic plaques correlates with the cardiovascular risk profile of patients
  15. Editorial: Functional Imaging of Inflammation and Infection
  16. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer
  17. 18F-FDG-PET/CT imaging of uterine cervical cancer recurrence in women with and without HIV infection
  18. The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml
  19. Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in Patients with Bladder Cancer
  20. Cardiovascular disturbances in COVID-19: an updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2
  21. Correlation Between CT Features of Active Tuberculosis and Residual Metabolic Activity on End-of-Treatment FDG PET/CT in Patients Treated for Pulmonary Tuberculosis
  22. A Prospective Investigation of Tumor Hypoxia Imaging with 68Ga-Nitroimidazole PET/CT in Patients with Carcinoma of the Cervix Uteri and Comparison with 18F-FDG PET/CT: Correlation with Immunohistochemistry
  23. [68 Ga]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint?
  24. Radionuclide Imaging of Invasive Fungal Disease in Immunocompromised Hosts
  25. Practical Considerations When Interpreting FDG PET/CT Imaging for Staging and Treatment Response Assessment in Melanoma Patients
  26. COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks
  27. Pattern of Prostate Cancer Recurrence Assessed by 68Ga-PSMA-11 PET/CT in Men Treated with Primary Local Therapy
  28. Imaging dysregulated calcium homeostasis in acute myocardial infarction with [68 Ga]Ga-NODAGAZOL
  29. Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
  30. Correction to: Global experience with PSMA‑based alpha therapy in prostate cancer
  31. PSMA Theranostics: Science and Practice
  32. Immune reconstitution inflammatory syndrome‐associated Graves disease in HIV‐infected patients: clinical characteristics and response to radioactive iodine therapy
  33. Global experience with PSMA-based alpha therapy in prostate cancer
  34. The Association of Tumor Burden by 18F-FDG PET/CT and Survival in Vulvar Carcinoma
  35. Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach
  36. Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: A case report
  37. [68Ga]Ga-Pentixafor for PET Imaging of Vascular Expression of CXCR-4 as a Marker of Arterial Inflammation in HIV-Infected Patients: A Comparison with 18F[FDG] PET Imaging
  38. FDG PET/CT for evaluating systemic arterial inflammation induced by anthracycline-based chemotherapy of Hodgkin lymphoma
  39. 18F-FDG PET/CT imaging of vulva cancer recurrence: A comparison of PET-derived metabolic parameters between women with and without HIV infection
  40. Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research
  41. Diagnostic value of sentinel lymph node scintigraphy and 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the detection of metastatic lymph nodes in patients with early-stage cervical cancer
  42. Molecular imaging of cardiovascular inflammation and infection in people living with HIV infection
  43. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases
  44. Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer
  45. 68Ga-PSMA: a One-stop Shop in Radioactive Iodine Refractory Thyroid Cancer?
  46. Imaging Tuberculosis and AIDS Associated Infections
  47. Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis
  48. 18F-FDG PET/CT as a Noninvasive Biomarker for Assessing Adequacy of Treatment and Predicting Relapse in Patients Treated for Pulmonary Tuberculosis
  49. Impact of optimized PET imaging conditions on 18F-FDG uptake quantification in patients with apparently normal aortas
  50. Correction to: 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
  51. Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617
  52. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy
  53. Fluorodeoxyglucose Positron Emission Tomography integrated with computed tomography in carcinoma of the cervix: Its impact on accurate staging and the predictive role of its metabolic parameters
  54. Radionuclide imaging of inflammation in atherosclerotic vascular disease among people living with HIV infection: current practice and future perspective
  55. South African guidelines for receptor radioligand therapy (RLT) with Lu-177-PSMA in prostate cancer
  56. 18F-FDG-PET metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with Hodgkin lymphoma
  57. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
  58. Prognostic Value of Pre-treatment F-18 FDG PET Metabolic Metrics in Patients with Locally Advanced Carcinoma of the Anus with and without HIV Infection
  59. 68 GaPSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?
  60. The optimal TSH level necessary for successful radioiodine ablation of differentiated thyroid carcinoma, as well as the time to reach this level, is a work in progress
  61. Monitoring Response to Therapy
  62. Arterial inflammation in young patients with human immunodeficiency virus infection: A cross-sectional study using F-18 FDG PET/CT
  63. Reply: Molecular Imaging of Bacteria in Patients Is an Attractive Fata Morgana, Not a Realistic Option
  64. Intra-individual comparison of18F-PSMA-1007 and18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: A pilot study
  65. Salivary Gland Activity Obscures Mandibular Metastasis of Prostate Carcinoma on 68Ga–Prostate-Specific Membrane Antigen PET
  66. 68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence
  67. Molecular imaging in musculoskeletal infections with 99mTc-UBI 29-41 SPECT/CT
  68. 68Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans
  69. Renal osteodystrophy presenting as a metabolic superscan on F-18 FDG PET/CT
  70. Metabolic Imaging of Infection
  71. The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma
  72. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT
  73. Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma
  74. 18F-FDG PET/CT in the detection of asymptomatic malignant melanoma recurrence
  75. F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infection
  76. Metastatic Prostate Carcinoma Presenting as a Superscan on 68Ga-PSMA PET/CT